SlideShare uma empresa Scribd logo
1 de 38
Rex Osborn
HealthCare Informatics
Idea Architect

Agility Health International

1
Agility Brand Suites

3
Introduction

A practical bridge between BioInformatics & HealthCare IT…

4
I. The Idea
II. The Market
III. Patentable Technology
IV. Defining Personalized Medicine
V. Relevance of Personalized Medicine
VI. Challenges of Personalized Medicine
VII.Pharmacogenomics
VIII.Cost Impetus
IX. Closed Loop Medication / Genome enabled
X. Sequencing to DICOM

5
The Idea
Today bioinformatics & healthcare information technology (HIT) does not provide a
practical nexus. The scientific & clinician genomic model is dissimilar & does NOT
take into consideration; clinician workflow, HIT standards, CPOE & the rightful
place within ―closed-loop-medication‖ to ensure patient safety. Without bridging
bioinformatic & HIT - ―Personalized Medicine‖ will never be realized.
Challenges in the exponential size of genomic data & controversy in how to manage
that data is the gateway for credibility & revenue. Agility Genomics has a plan and
engineering approach , as well as the team to bridge the Pharmacogenomic
components of bioinformatics to the EHR. Making sequenced DNA clinically
relevant.
Furthermore we enable Personalized Medicine by providing clinically germane
genome data to the patient’s PHR. Today intelligent storage, tomorrow the
management of secondary data.
6
Practical interoperability; BioInformatics & the EHR
The Idea
We propose a new business that provides “sequenced” Genomic storage, management & clinical
decision content for CPOE / EHR solutions; Bridging BioInformatics capacity to manage a sequenced
genome into a practical HL7 feed for clinicians EHR
Phase I. Genomic Data Storage (DICOM / HL7) – National Library of Medicine / National Institute
Health Genomic Program / Grant (Genome raw data to DICOM)

Phase II. Apply Intelligent HSM & HIPAA encryption to genetic data elements
Phase III. Develop genomic ―ontology‖ leveraging standards to initiate parsing & aggregation of
structured data (HealthLanguage)
Phase IV. Develop clinical decision support (CDS) mechanism to convey Pharmacogenomic data @ the
point of care (CPOE) (www.warfarindosing.org)
Phase V. Commercialize DNA archive & analysis for forensic products (Services: storage, integration &
aggregation to HL7)

7
Clinical Annotation of Patient Genomic Data within the EHR
The Approach
STORAGE OF WHOLE PATIENT GENOMES ACCESSIBLE VIA YOUR EHR

 DICOM-based format w/ HL7 relevant data (MPI, PIX, PID etc)
 Fast transfer in & out of EHR
 Parsing, aggregation & mining for public / research / private output
PHARMACOGENOMIC CLINICAL DECISION SUPPORT (CDS)

 Generic algorithms for the EHR
 Tethered, secure service
 Drug – Genome clinical content for critical decision making @ POC ―CPOE‖
NOSOLOGY-BASED GENOME SEARCH FUNCTIONS: EHR

 Provides clinician quick search to identify disease mutations
 Will also offer OTS applications for genome analysis – M&A
 Disease predisposition characteristic availability

Agility sells software, services & secure cloud access through EHR & PHR suppliers. Leveraging our work
with research institutions sharing, storing and managing genetic data packets. Our adherence to HIPAA,
GINA, DICOM, HL7, HIPAA will enable a practical path to Personalized Medicine (healthcare tailored to
each individual's genetic makeup).

www.warfarindosing.org

8
The Market
Market Impetus:

According to the report:

Currently, it costs about $1,000 to sequence an entire
human genome; That cost will be lowered to about $100
per patient by the year 2012, making it feasible to sequence
individual patient genomes & store them in the EHR.
Upside for Agility = the cost of storage and of the analyzed
genome will be significant.

The core diagnostic and therapeutic segment of the
market – comprised primarily of pharmaceutical,
medical device & diagnostics companies – is estimated
at $24 billion and is expected to grow by 10 percent
annually, reaching $42 billion by 2015.

Market Size; The market for Personalized Medicine in the
United States is already $232 billion, and it is projected to
grow 11% annually, according to a new report published
today by PricewaterhouseCoopers LLP

The personalized medical care portion of the market –
including telemedicine, health information technology
& disease management services offered by traditional
health & technology companies – is estimated at $4
billion to $12 billion and could grow tenfold to over
$100 billion by 2015 if telemedicine takes off.
The related nutrition and wellness market – including
retail, complementary and alternative medicine offered
by consumer products, food and beverage, leisure and
retail companies – is estimated at $196 billion and is
projected to grow 7 percent annually to over $290
billion by 2015.

9
Market Focus
Initial

Secondary

Tertiary

Future

10
Patentable Technology
1) A DICOM Method for Storage of Human Genomic Data
2) Searchable Human Genomic Data by Nosology
3) Generalized, Allele-Specific Algorithms for
Pharmacogenetic Clinical Decision Support (CDS)
4) Fast Transfer of Genomic Data to an XML-based
Electronic Health Record (EHR)
5) Genomic-based XDS clinical connectivity (associate
relevant clinical documentation)
6) Clinical content with ―ontology‖ for CPOE CDS
solutions (conveyance method)
7) Genomic data encryption & access audit (HIPAA based)
that meets GINA (2008 Genomic Legislation)
8) Patent transition methodology moving ―sequenced DNA‖
raw data to DICOM stored for conveyance to output of
HL7 message relaying clinical content to CDS / CPOE /
EHR

11
Defining Personalized Medicine
Personalized Medicine—also called Genome-based
or Genomic Medicine
Personalized Medicine analyzes a person’s molecular
information to determine their propensity for
developing certain diseases, including a disease’s
potential onset & course. It also determines a
person’s susceptibility for responding to different
drug therapies, by determining the ability to
metabolize drugs &/or likelihood of experiencing
adverse drug reactions (ADR). The term
personalized medicine is often used in place of the
scientific term Pharmacogenomics.

Bioinformatics is using computers to solve problems
in biology. Bioinformatics is a scientific discipline
that encompasses all aspects of biological
information acquisition, processing, storage,
distribution, analysis and interpretation.
Bioinformatics combines the tools of Biology,
Chemistry, Mathematics, Statistics & Computer
Science to understand and model biological
processes.

Genetics is the study of heredity & genetic medicine,
it examines the role of individual genes as they relate
to biology and medicine.
Genomic medicine makes use of our own personal
(thus the name, personalized medicine) genome - our
individual genetic structure encoded by the nucleotide
sequences, etc. to determine an individuals
vulnerability to disease and responsiveness to
medication.

Personalized Medicine is the Outcome of Genomic Medicine

12
Relevance of Personalized Medicine

Goals of Personalized Medicine allowing clinicians
to…


Predict Disease pre-symptomatically with
simple testing



Prevent Disease by identifying risks, early
interventions



Diagnose Conditions less invasively, more
accurately



Select Drugs that maximize benefits &
minimize risks



Calibrate Treatments to heighten proven
efficacy & recovery



Stable Genomics (Inherited Genes)
– BRCA 1 & 2 predictor of breast and
ovarian cancer risks
– LDLR and APOB predictor of
developing early coronary artery disease
– MODY 1-6 predictor of MODY diabetes;
subtypes affect treatment choice
– CYP2D6/C19 Main cytochrome P450
genes that affects drug metabolism 
dosing
– CYP2C9/VKORC1 variants in these
cP450 genes affect warfarin metabolism
– TPMT guides adjustment of Purinethol
dosing in Acute Leukemia patients

Treat/Cure Disease using our own genes

Dynamic Genomics (Gene Expression, Biomarkers…)
– Estrogen Receptor predicts response to
Tamoxifen in breast cancer
– HER-2 Receptor predicts response to
Herceptin in breast cancer
– PSA predicts risk of prostate cancer
– Cholesterol predicts risk of heart disease
and strokes
– HIV Genotyping to guide selection of
therapy
– PET Scans to diagnose and help manage
treatment options for various cancers

13

Practical Use of Genomic Medicine
Challenges of Personalized Medicine
Application of data integration concepts &
approaches to genomic medicine
 Data warehouse approaches
 Database federation approaches
 Peer data management system approaches
 Ontologies
 Semi-structured data
Gaps remaining in data integration both clinical &
research to facilitate genomic medicine
 Data availability
 Privacy issues (HIPAA)
 Data issues
 Scalability
 Standards adoption Bridging disciplines:
collaborations vs convergence

TACTICALLY
 Storage - large and diverse data sets.
 Intelligent Hierarchical Archive Management
 DICOMization of Raw Data
 Integration of HL7 data; MPI, CDR & History
 National Library of Medicine (NLM) = Genetic
Data Management ―Research‖
 HIPAA – Genetic Data Encryption
STRATEGICALLY
 Ontology – MeSH, UMLS, Ontofusion, SnoMeds
 Patent Workflow, Management, Parsing,
Aggregation & Mining
 XDS
 Limited tools for appropriate standardization of
findings
 CRO – Clinical Research Organization
 Genome based CDS
 Provide genomic content for CDS

14
Challenges of Personalized Medicine

15
Commoditization
 The cost of sequencing and analysis of an
entire human genome will drop to about
$100 by 2012 (from Dr. George Church,
Broad Institute, MIT/Harvard).
 This will effectively require a new storage &
data management scheme to handle Genomic
data that has been sequenced.

 Sequenced genomic data & analysis of this
data to convey via a ―patentable‖ ontology in
existing EHRs (the ability to communicate
with disparate systems is a ―must‖)
 Although Clinical Decision Support /
Clinical Content is paramount & the ultimate
goal for evidence based medicine, outcomes
based medicine and to mitigate medication
risk, the short term opportunity is in
intelligent storage

16
Historical trends in storage prices vs
DNA sequencing costs

17
Pharmacogenomics
Opportunities will increase the value of the
drugs being developed using Genomic /
Genetic Medicine:
 Obtain greater understanding of disease
 Predict disease severity, onset,
progression
 Identify genetic subtypes of disease
 Lower ADRs in Clinical setting
 Lower unknown contraindications
 Aid in discovery of new drug targets
 Distinguish subgroups of patients who
respond differently to drug treatment
 Aid interpretation of clinical study
results
 Evolution of Pharmacogenetics –
advancing requirements for research &
clinical trial environments
18

Average Cost to Develop a Medication in the US $800 Million USD
Evaluate
Order

Obtain
medication
related
history

Sequenced Genomic
Data; Managed,
Archived, Parsed,
Aggregated & available
@ the Point of Care
CPOE

Documentati
on
medication
history &
updates

Intervene
as
indicated
for ADR
errors

Select
Medication

Prepare
Medication

Dispense /
Dist. IV &
Medication

CIS/CDS
/CDR

Assess & document
patient response to
medication
according to
defined parameters

Closed Loop Medication Workflow w/ Genomic CDS

Educate
patient
regarding
medication

Educate staff
regarding
medications

19
Sequencing to DICOM
MAPPING

Identify set of clones that span region
of genome to be sequenced

LIBRARY
CREATION

Purify DNA from smaller clones
Setup & perform sequencing chemistries

Make sets of smaller clones
from mapped clones

TEMPLATE
PREPERATION

Determine sequences from smaller clones

Specialty techniques to produce
high quality sequences

DATA EDITING
/ ANNOTATION

GENOME
SEQUENCING

PRE-FINISHING
& FINISHING
Quality assurance
Verification
Biological annotation
Submission to public DB
21
Clinical Decision Support
 Today, at best …
 Population based-evidence combined
with individual clinician experience
 Calculators, nomograms and criteria to
risk stratify individuals

Clinical Decision Support - The act of
providing clinicians, patients and other health
care stakeholders with pertinent knowledge
and/or person specific information,
intelligently filtered or presented at
appropriate times

 CDS systems with 4 critical features significantly
improved clinical practice in 94% of RCTs
 Tomorrow, decision making will be …
 Phenotype, environmental, clinical, and
genomic factors in a ―black box‖ risk
model
 Patient and physician will need to
interpret meaning of risk
 Personalized medicine complements
evidence-based medicine

(Kawamoto et al., 2005):

1) automatic provision of CDS as part of
clinician workflow
2) provision of recommendations
3) provision of CDS at time & location of
decision making
4) computer-based generation of the CDS
23
Key Interfaces

24
Workflow
Agility Software - Input
1. Lab Test / Lab
2. DNA Sequence (SNPs & Genome)
3. DICOM Transport & Query Retrieve
4. Encryption & Audit Initiated
5. Genomic Research - Genotype
6. Screening – Genotype
7. Molecular / Medical Imaging – Genotype,
Phenotype & Environment

Agility Future Software & Services
10. Integrated – Genotype & Phenotype
assessment for inherited & common
conditions
11. EHR Portal enabled
12. Genome-based Clinical Decision Support

(clinical content or ―full‖ logic for direct CPOE
communiqués)

13. Provider Portal enabled
14. Public health / syndromic Portal enabled
15. PHR Portal enabled

Agility Software & Services - Output
8. Archive
9. Research Database – parsing, aggregation
& mining
10. Interface (current chasm) – LIS, PACS /
RIS, CVIS, HIS, EHR & EDMS (Electronic
Doc Mgt. System)

25
Building Blocks
PERSONALIZED

Biologic
Sciences

Informatics
& HCIT
Molecular
Basis of
Disease

Novel
Therapies
Disease
Subtypes

MEDICINE

EHR
Adoption
BioStat
Modeling

Molecular
Diagnostics
Clinical
Database
―Data
warehouse‖

Genomics

Epigenetics
Proteomics

26
Marketing Considerations
Marketing Strategy
 Competitive Positioning
 Brand Strategy
 Pricing
 Distribution Channels
 Sales Process
 Marketing Campaigns
 Marketing Plans

Managing Sales & Marketing
 Business Development
 Telemarketing
 Sales Management
 Direct Mail
 Email Marketing
 Search Engine Marketing
 Trade Shows
 Publicity
 Customer Retention
 Traditional Media
 Online Advertising
 Social Media

Tools & Processes
 Naming
 Messaging
 Corporate Identity
 Sales Literature (Collateral)
 Sales Content
 Website - Blog
 CRM

27
Horizontal Styled SWOT
Strength

Weakness

Incredible growth, and
investment
Tactically we can leverage
Existing Client Base
• Highlight storage, scalability
& encryption
• Flexibility of HSM
• Cloud Computing /
Archiving
• Huge Data Sets

Integration chasm & output
requires investment &
development of software,
resources & related services.
Requires a move to a new
clinical & bioinformatics
vertical.

Opportunity

Evolution of Image archiving
means going beyond the walls
of Radiology & Cardiology –
diversification of current
product suite offers
advantages as does growing
market & new discipline.
HHS will require genomic
data embedded in to the EHR
2012 enforcement 2014

Threat

Market vertical is growing &
commoditization will require
FDA to regulate & CMS to
make procedure viable
―reimbursement challenge‖
―genomic information
exchange‖ very academic
presently – the move from Bio
to HIT has challenges

28
Reference Material









The Human Genome Project: www.genome.gov
The NUGene Project: www.NUGene.org
Clinical Proteomics Project: http://proteomics.cancer.gov
The FDA and Genomics: www.fda.gov/cder/genomics
The CDC and Genomics: www.cdc.gov/genomics/default.htm
NIH & Pharmacogenetics: www.nigms.nih.gov/Initiatives/PGRN
Non-Profit Organizations
 http://bioitalliance.org
 http://www.personalizedmedicinecoalition.org
 News and Updates
 http://www.ageofpersonalizedmedicine.org
 http://www.genomenewsnetwork.org/

29
Image Relation

Imaging Visual Reference

30
Imaging + Genomics Data

31
Gene regulation:
TIGR MeV + CAVEman
Gene expression
datasets are initially
analysed using the
MultiExperiment
Viewer.
Patterns of interest are
visualized as animated
color maps directly on
the chosen organs.

32
Pharmacokinetics

500mg Aspirin (acetylsalicylic acid) example
Processes: Absorption > distribution > metabolism > excretion (ADME)
Systems: alimentary > cardiovascular > urinary
33
4D ADME Visualization (a)
(Absorption, Distribution, Metabolism, Elimination)

ABSORPTION
The original compound (e.g.
acetylsalicylic acid or
acetaminophen) is shown in red
and is first absorbed through the
digestive organs.

34
4D ADME Visualization (b)
DISTRIBUTION,
METABOLISM
Simultaneously with its absorption
into the blood stream, it is being
metabolized into derivative
compounds, shown in green
(e.g. salicylic acid,
acetaminophen sulfate,
acetaminophen glucuronide,
etc.), which are distributed
throughout the body.

35
4D ADME Visualization (c)
ELIMINATION
Eventually all compounds are
eliminated from the blood and
are excreted through the urinary
system

36
Drug modeling:
Aspirin, Tylenol, Prozac, Lipitor

37
Exploring complex
4D data along any axis
(with Dr. Benedikt Hallgrímsson, U of C)

Sagittal

Frontal

Right: Integration, quantification and
visualization of data in 3D / 4D

Averaged

Above: 3D morphometric (micro-CT)
and cell proliferation (histochemistry) data
in mouse embryos

Embryo 2

Embryo 1

External

38
Data integration mechanism

Gene Expression Omnibus

Terminologia Anatomica

Cytomer

GSM88529 : Cardiac

A12.1.00.001
Heart

Heart

GSM88484 : Coronary artery

A12.2.03.101
Right coronary artery

Right coronary artery

A12.2.03.201
Left coronary artery

Left coronary artery

A06.5.01.002
Right lung

Left inferior pulmonary lobe

A06.5.01.003
Left lung

Middle lobe of right lung

GSM88522 : Lung

Left superior pulmonary lobe

Right inferior pulmonary lobe
Right superior pulmonary lobe

Terminological discrepancies between ontologies make integration difficult.
39
Ontology support:
All data sources are connected

Domains ontologies are
semantically related.
Data sources are indexed via
ontologies.
Visualization device may be
either a virtual reality (e.g.,
CAVE) or a common
desktop.

40
Future research directions
Model more molecular & anatomical processes
Develop more variety of interactions
Utilize more human body models
– Female, child

Genetic Variation

Pathways

Cellular Processes

Phenotypes
41

Mais conteúdo relacionado

Mais procurados

Health informatics : How to increase it’s utilization from data display to de...
Health informatics : How to increase it’s utilization from data display to de...Health informatics : How to increase it’s utilization from data display to de...
Health informatics : How to increase it’s utilization from data display to de...Dr Vijay Raaghavan
 
Healthcare Whitepaper
Healthcare WhitepaperHealthcare Whitepaper
Healthcare WhitepaperEdgevalue
 
Establishing Cognizant In EMR Market
Establishing Cognizant In EMR MarketEstablishing Cognizant In EMR Market
Establishing Cognizant In EMR MarketEternaljoy
 
A novel framework for electronic global
A novel framework for electronic globalA novel framework for electronic global
A novel framework for electronic globalhiij
 
D1 1150 low cheng ooi sharing singapore's experience on the nehr a-pe_hrc h...
D1 1150 low cheng ooi sharing singapore's experience on the nehr   a-pe_hrc h...D1 1150 low cheng ooi sharing singapore's experience on the nehr   a-pe_hrc h...
D1 1150 low cheng ooi sharing singapore's experience on the nehr a-pe_hrc h...Dr. Wilfred Lin (Ph.D.)
 
Role of In Vitro Diagnostics in Saudi Arabia
Role of In Vitro Diagnostics in Saudi ArabiaRole of In Vitro Diagnostics in Saudi Arabia
Role of In Vitro Diagnostics in Saudi ArabiaSolidiance
 
Ehr by jessica austin, shaun baker, victoria blankenship and kayla boro
Ehr by jessica austin, shaun baker, victoria blankenship and kayla boroEhr by jessica austin, shaun baker, victoria blankenship and kayla boro
Ehr by jessica austin, shaun baker, victoria blankenship and kayla borokayla_ann_30
 
SpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPTSpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPTCrystal Research Associates
 
Catasys, Inc. Executive Informational Overview Introduction
Catasys, Inc. Executive Informational Overview IntroductionCatasys, Inc. Executive Informational Overview Introduction
Catasys, Inc. Executive Informational Overview IntroductionCrystal Research Associates
 
It Infrastructure Of Indian Hospitals1
It Infrastructure Of Indian Hospitals1It Infrastructure Of Indian Hospitals1
It Infrastructure Of Indian Hospitals1Pooja Panchal
 
Latin America´s Role In Clinical Studies
Latin America´s Role In Clinical StudiesLatin America´s Role In Clinical Studies
Latin America´s Role In Clinical StudiesPAREXEL International
 
Indices, Registries, And Databases
Indices, Registries, And DatabasesIndices, Registries, And Databases
Indices, Registries, And DatabasesLori Powers
 
Patient confidentiality: Ethical and legal ramifications
Patient confidentiality: Ethical and legal ramificationsPatient confidentiality: Ethical and legal ramifications
Patient confidentiality: Ethical and legal ramificationsArete-Zoe, LLC
 
Group project health_care_informatics[2
Group project health_care_informatics[2Group project health_care_informatics[2
Group project health_care_informatics[2guest1e610e
 
Pulmonary Symposium Presentation on Critical Care
Pulmonary Symposium Presentation on Critical CarePulmonary Symposium Presentation on Critical Care
Pulmonary Symposium Presentation on Critical CareJohn Zaleski
 
The Vision of Independent Health Record Banks
The Vision of Independent Health Record BanksThe Vision of Independent Health Record Banks
The Vision of Independent Health Record BanksWCIT 2014
 

Mais procurados (20)

Health informatics : How to increase it’s utilization from data display to de...
Health informatics : How to increase it’s utilization from data display to de...Health informatics : How to increase it’s utilization from data display to de...
Health informatics : How to increase it’s utilization from data display to de...
 
Healthcare Whitepaper
Healthcare WhitepaperHealthcare Whitepaper
Healthcare Whitepaper
 
HM312 Week 1 part 1 of 2
HM312 Week 1 part 1 of 2HM312 Week 1 part 1 of 2
HM312 Week 1 part 1 of 2
 
Establishing Cognizant In EMR Market
Establishing Cognizant In EMR MarketEstablishing Cognizant In EMR Market
Establishing Cognizant In EMR Market
 
HM312 Week 7
HM312 Week 7HM312 Week 7
HM312 Week 7
 
A novel framework for electronic global
A novel framework for electronic globalA novel framework for electronic global
A novel framework for electronic global
 
D1 1150 low cheng ooi sharing singapore's experience on the nehr a-pe_hrc h...
D1 1150 low cheng ooi sharing singapore's experience on the nehr   a-pe_hrc h...D1 1150 low cheng ooi sharing singapore's experience on the nehr   a-pe_hrc h...
D1 1150 low cheng ooi sharing singapore's experience on the nehr a-pe_hrc h...
 
Role of In Vitro Diagnostics in Saudi Arabia
Role of In Vitro Diagnostics in Saudi ArabiaRole of In Vitro Diagnostics in Saudi Arabia
Role of In Vitro Diagnostics in Saudi Arabia
 
Ehr by jessica austin, shaun baker, victoria blankenship and kayla boro
Ehr by jessica austin, shaun baker, victoria blankenship and kayla boroEhr by jessica austin, shaun baker, victoria blankenship and kayla boro
Ehr by jessica austin, shaun baker, victoria blankenship and kayla boro
 
SpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPTSpectraScience SCIE Executive Informational Overview PPT
SpectraScience SCIE Executive Informational Overview PPT
 
Catasys, Inc. Executive Informational Overview Introduction
Catasys, Inc. Executive Informational Overview IntroductionCatasys, Inc. Executive Informational Overview Introduction
Catasys, Inc. Executive Informational Overview Introduction
 
It Infrastructure Of Indian Hospitals1
It Infrastructure Of Indian Hospitals1It Infrastructure Of Indian Hospitals1
It Infrastructure Of Indian Hospitals1
 
Latin America´s Role In Clinical Studies
Latin America´s Role In Clinical StudiesLatin America´s Role In Clinical Studies
Latin America´s Role In Clinical Studies
 
Indices, Registries, And Databases
Indices, Registries, And DatabasesIndices, Registries, And Databases
Indices, Registries, And Databases
 
Patient confidentiality: Ethical and legal ramifications
Patient confidentiality: Ethical and legal ramificationsPatient confidentiality: Ethical and legal ramifications
Patient confidentiality: Ethical and legal ramifications
 
Group project health_care_informatics[2
Group project health_care_informatics[2Group project health_care_informatics[2
Group project health_care_informatics[2
 
Medical informatics report
Medical informatics reportMedical informatics report
Medical informatics report
 
Pulmonary Symposium Presentation on Critical Care
Pulmonary Symposium Presentation on Critical CarePulmonary Symposium Presentation on Critical Care
Pulmonary Symposium Presentation on Critical Care
 
Meaningful use basics
Meaningful use basicsMeaningful use basics
Meaningful use basics
 
The Vision of Independent Health Record Banks
The Vision of Independent Health Record BanksThe Vision of Independent Health Record Banks
The Vision of Independent Health Record Banks
 

Destaque

DatCard Agilisys "Adaptive Image eXchange" AIX
DatCard Agilisys "Adaptive Image eXchange" AIXDatCard Agilisys "Adaptive Image eXchange" AIX
DatCard Agilisys "Adaptive Image eXchange" AIXRex Osborn
 
FOSE-2013-RROv4.5
FOSE-2013-RROv4.5FOSE-2013-RROv4.5
FOSE-2013-RROv4.5Rex Osborn
 
Imaging evolution-himss-middle east09-v5.0
Imaging evolution-himss-middle east09-v5.0Imaging evolution-himss-middle east09-v5.0
Imaging evolution-himss-middle east09-v5.0Rex Osborn
 
Chiorino Fast Joint Press Kits
Chiorino Fast Joint Press KitsChiorino Fast Joint Press Kits
Chiorino Fast Joint Press KitsBeltman2000
 
R osborn rad-onc-101.2013
R osborn rad-onc-101.2013R osborn rad-onc-101.2013
R osborn rad-onc-101.2013Rex Osborn
 
LinkedIn Sales Executive MS Dynamics Integration
LinkedIn Sales Executive MS Dynamics Integration LinkedIn Sales Executive MS Dynamics Integration
LinkedIn Sales Executive MS Dynamics Integration Eanna Kenny
 
خصائص الخلايا الجذعية السرطانية
خصائص الخلايا الجذعية السرطانية خصائص الخلايا الجذعية السرطانية
خصائص الخلايا الجذعية السرطانية Ghmkin Hsn
 
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)Oral_Path_Conf
 
محاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجمحاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجmadanialgerie
 
محاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجمحاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجwassimalgerie
 
الخلايا الجذعية البالغة
الخلايا الجذعية البالغةالخلايا الجذعية البالغة
الخلايا الجذعية البالغةGhmkin Hsn
 
الكشف المبكر عن سرطان الفم
الكشف المبكر عن سرطان الفمالكشف المبكر عن سرطان الفم
الكشف المبكر عن سرطان الفمMohamed A. Galal
 
الخلايا الجذعية السرطانية مقدمة
الخلايا الجذعية السرطانية مقدمةالخلايا الجذعية السرطانية مقدمة
الخلايا الجذعية السرطانية مقدمةGhmkin Hsn
 

Destaque (15)

DatCard Agilisys "Adaptive Image eXchange" AIX
DatCard Agilisys "Adaptive Image eXchange" AIXDatCard Agilisys "Adaptive Image eXchange" AIX
DatCard Agilisys "Adaptive Image eXchange" AIX
 
FOSE-2013-RROv4.5
FOSE-2013-RROv4.5FOSE-2013-RROv4.5
FOSE-2013-RROv4.5
 
Imaging evolution-himss-middle east09-v5.0
Imaging evolution-himss-middle east09-v5.0Imaging evolution-himss-middle east09-v5.0
Imaging evolution-himss-middle east09-v5.0
 
Chiorino Fast Joint Press Kits
Chiorino Fast Joint Press KitsChiorino Fast Joint Press Kits
Chiorino Fast Joint Press Kits
 
R osborn rad-onc-101.2013
R osborn rad-onc-101.2013R osborn rad-onc-101.2013
R osborn rad-onc-101.2013
 
LinkedIn Sales Executive MS Dynamics Integration
LinkedIn Sales Executive MS Dynamics Integration LinkedIn Sales Executive MS Dynamics Integration
LinkedIn Sales Executive MS Dynamics Integration
 
خصائص الخلايا الجذعية السرطانية
خصائص الخلايا الجذعية السرطانية خصائص الخلايا الجذعية السرطانية
خصائص الخلايا الجذعية السرطانية
 
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)
ملخص (سرطان الفم تعرف عليه، وكيف تكشفه مبكرا؟)
 
salivaomics by Dr.Ilakkiya Balasubramaniyan
salivaomics by Dr.Ilakkiya Balasubramaniyansalivaomics by Dr.Ilakkiya Balasubramaniyan
salivaomics by Dr.Ilakkiya Balasubramaniyan
 
محاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجمحاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاج
 
محاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاجمحاضرة الآفات الاجتماعية الظاهرة والعلاج
محاضرة الآفات الاجتماعية الظاهرة والعلاج
 
الخلايا الجذعية البالغة
الخلايا الجذعية البالغةالخلايا الجذعية البالغة
الخلايا الجذعية البالغة
 
الكشف المبكر عن سرطان الفم
الكشف المبكر عن سرطان الفمالكشف المبكر عن سرطان الفم
الكشف المبكر عن سرطان الفم
 
Cell & Molecular Biology
Cell & Molecular BiologyCell & Molecular Biology
Cell & Molecular Biology
 
الخلايا الجذعية السرطانية مقدمة
الخلايا الجذعية السرطانية مقدمةالخلايا الجذعية السرطانية مقدمة
الخلايا الجذعية السرطانية مقدمة
 

Semelhante a Agility v7.0-rro

Bioinformatics
BioinformaticsBioinformatics
BioinformaticsJTADrexel
 
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)Hellmuth Broda
 
The Path to Wellness through Big Data
The Path to Wellness  through Big Data The Path to Wellness  through Big Data
The Path to Wellness through Big Data Hortonworks
 
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...Health Catalyst
 
Use of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentUse of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentEMMAIntl
 
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew Litt
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew LittHealthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew Litt
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew LittD3 Consutling
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
 
Simplifying semantics for biomedical applications
Simplifying semantics for biomedical applicationsSimplifying semantics for biomedical applications
Simplifying semantics for biomedical applicationsSemantic Web San Diego
 
Introduction to Pharma and Healthcare IT-Anirban
Introduction to Pharma  and Healthcare IT-AnirbanIntroduction to Pharma  and Healthcare IT-Anirban
Introduction to Pharma and Healthcare IT-AnirbanDr. Anirban Mukherjee, PhD
 
Accelerating the benefits of genomics worldwide
Accelerating the benefits of genomics worldwideAccelerating the benefits of genomics worldwide
Accelerating the benefits of genomics worldwideJoaquin Dopazo
 
Precision Prospects - Genomics Medicine
Precision Prospects - Genomics MedicinePrecision Prospects - Genomics Medicine
Precision Prospects - Genomics MedicineHeather Fraser
 
Realising the potential of Health Data Science: opportunities and challenges ...
Realising the potential of Health Data Science:opportunities and challenges ...Realising the potential of Health Data Science:opportunities and challenges ...
Realising the potential of Health Data Science: opportunities and challenges ...Paolo Missier
 
ppt for data science slideshare.pptx
ppt for data science slideshare.pptxppt for data science slideshare.pptx
ppt for data science slideshare.pptxMangeshPatil358834
 
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in Healthcare
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in HealthcareNavigating Healthcare's Seas: Unraveling the Power of Data Mining in Healthcare
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in HealthcareThe Lifesciences Magazine
 
Health Informatics- Module 1-Chapter 1.pptx
Health Informatics- Module 1-Chapter 1.pptxHealth Informatics- Module 1-Chapter 1.pptx
Health Informatics- Module 1-Chapter 1.pptxArti Parab Academics
 
Nikhil anmol pres_092014_1.0_final_2222
Nikhil anmol pres_092014_1.0_final_2222Nikhil anmol pres_092014_1.0_final_2222
Nikhil anmol pres_092014_1.0_final_2222nikhilaptsi
 
Accelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World EvidenceAccelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World EvidenceCitiusTech
 
Big Data Analytics in the Health Domain
Big Data Analytics in the Health DomainBig Data Analytics in the Health Domain
Big Data Analytics in the Health DomainBigData_Europe
 

Semelhante a Agility v7.0-rro (20)

Bioinformatics
BioinformaticsBioinformatics
Bioinformatics
 
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)
Big Data and its Impact on Industry (Example of the Pharmaceutical Industry)
 
The Path to Wellness through Big Data
The Path to Wellness  through Big Data The Path to Wellness  through Big Data
The Path to Wellness through Big Data
 
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Person...
 
Use of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentUse of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test Development
 
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew Litt
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew LittHealthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew Litt
Healthcare Conference 2013 : Genes, Clouds and Cancer - dr. Andrew Litt
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 
Simplifying semantics for biomedical applications
Simplifying semantics for biomedical applicationsSimplifying semantics for biomedical applications
Simplifying semantics for biomedical applications
 
2016 iHT2 San Diego Health IT Summit
2016 iHT2 San Diego Health IT Summit2016 iHT2 San Diego Health IT Summit
2016 iHT2 San Diego Health IT Summit
 
Introduction to Pharma and Healthcare IT-Anirban
Introduction to Pharma  and Healthcare IT-AnirbanIntroduction to Pharma  and Healthcare IT-Anirban
Introduction to Pharma and Healthcare IT-Anirban
 
Accelerating the benefits of genomics worldwide
Accelerating the benefits of genomics worldwideAccelerating the benefits of genomics worldwide
Accelerating the benefits of genomics worldwide
 
Precision Prospects - Genomics Medicine
Precision Prospects - Genomics MedicinePrecision Prospects - Genomics Medicine
Precision Prospects - Genomics Medicine
 
Realising the potential of Health Data Science: opportunities and challenges ...
Realising the potential of Health Data Science:opportunities and challenges ...Realising the potential of Health Data Science:opportunities and challenges ...
Realising the potential of Health Data Science: opportunities and challenges ...
 
Strand genomics features in CIO review
Strand genomics features in CIO reviewStrand genomics features in CIO review
Strand genomics features in CIO review
 
ppt for data science slideshare.pptx
ppt for data science slideshare.pptxppt for data science slideshare.pptx
ppt for data science slideshare.pptx
 
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in Healthcare
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in HealthcareNavigating Healthcare's Seas: Unraveling the Power of Data Mining in Healthcare
Navigating Healthcare's Seas: Unraveling the Power of Data Mining in Healthcare
 
Health Informatics- Module 1-Chapter 1.pptx
Health Informatics- Module 1-Chapter 1.pptxHealth Informatics- Module 1-Chapter 1.pptx
Health Informatics- Module 1-Chapter 1.pptx
 
Nikhil anmol pres_092014_1.0_final_2222
Nikhil anmol pres_092014_1.0_final_2222Nikhil anmol pres_092014_1.0_final_2222
Nikhil anmol pres_092014_1.0_final_2222
 
Accelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World EvidenceAccelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World Evidence
 
Big Data Analytics in the Health Domain
Big Data Analytics in the Health DomainBig Data Analytics in the Health Domain
Big Data Analytics in the Health Domain
 

Último

COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaborationbruanjhuli
 
Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Brian Pichman
 
Nanopower In Semiconductor Industry.pdf
Nanopower  In Semiconductor Industry.pdfNanopower  In Semiconductor Industry.pdf
Nanopower In Semiconductor Industry.pdfPedro Manuel
 
Comparing Sidecar-less Service Mesh from Cilium and Istio
Comparing Sidecar-less Service Mesh from Cilium and IstioComparing Sidecar-less Service Mesh from Cilium and Istio
Comparing Sidecar-less Service Mesh from Cilium and IstioChristian Posta
 
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfIaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfDaniel Santiago Silva Capera
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAshyamraj55
 
Building AI-Driven Apps Using Semantic Kernel.pptx
Building AI-Driven Apps Using Semantic Kernel.pptxBuilding AI-Driven Apps Using Semantic Kernel.pptx
Building AI-Driven Apps Using Semantic Kernel.pptxUdaiappa Ramachandran
 
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...UbiTrack UK
 
VoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXVoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXTarek Kalaji
 
AI You Can Trust - Ensuring Success with Data Integrity Webinar
AI You Can Trust - Ensuring Success with Data Integrity WebinarAI You Can Trust - Ensuring Success with Data Integrity Webinar
AI You Can Trust - Ensuring Success with Data Integrity WebinarPrecisely
 
Igniting Next Level Productivity with AI-Infused Data Integration Workflows
Igniting Next Level Productivity with AI-Infused Data Integration WorkflowsIgniting Next Level Productivity with AI-Infused Data Integration Workflows
Igniting Next Level Productivity with AI-Infused Data Integration WorkflowsSafe Software
 
AI Fame Rush Review – Virtual Influencer Creation In Just Minutes
AI Fame Rush Review – Virtual Influencer Creation In Just MinutesAI Fame Rush Review – Virtual Influencer Creation In Just Minutes
AI Fame Rush Review – Virtual Influencer Creation In Just MinutesMd Hossain Ali
 
Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.YounusS2
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1DianaGray10
 
Linked Data in Production: Moving Beyond Ontologies
Linked Data in Production: Moving Beyond OntologiesLinked Data in Production: Moving Beyond Ontologies
Linked Data in Production: Moving Beyond OntologiesDavid Newbury
 
COMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a WebsiteCOMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a Websitedgelyza
 
Machine Learning Model Validation (Aijun Zhang 2024).pdf
Machine Learning Model Validation (Aijun Zhang 2024).pdfMachine Learning Model Validation (Aijun Zhang 2024).pdf
Machine Learning Model Validation (Aijun Zhang 2024).pdfAijun Zhang
 
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...Aggregage
 
Designing A Time bound resource download URL
Designing A Time bound resource download URLDesigning A Time bound resource download URL
Designing A Time bound resource download URLRuncy Oommen
 

Último (20)

COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
 
Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )
 
Nanopower In Semiconductor Industry.pdf
Nanopower  In Semiconductor Industry.pdfNanopower  In Semiconductor Industry.pdf
Nanopower In Semiconductor Industry.pdf
 
Comparing Sidecar-less Service Mesh from Cilium and Istio
Comparing Sidecar-less Service Mesh from Cilium and IstioComparing Sidecar-less Service Mesh from Cilium and Istio
Comparing Sidecar-less Service Mesh from Cilium and Istio
 
20150722 - AGV
20150722 - AGV20150722 - AGV
20150722 - AGV
 
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfIaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
 
Building AI-Driven Apps Using Semantic Kernel.pptx
Building AI-Driven Apps Using Semantic Kernel.pptxBuilding AI-Driven Apps Using Semantic Kernel.pptx
Building AI-Driven Apps Using Semantic Kernel.pptx
 
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...
UWB Technology for Enhanced Indoor and Outdoor Positioning in Physiological M...
 
VoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXVoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBX
 
AI You Can Trust - Ensuring Success with Data Integrity Webinar
AI You Can Trust - Ensuring Success with Data Integrity WebinarAI You Can Trust - Ensuring Success with Data Integrity Webinar
AI You Can Trust - Ensuring Success with Data Integrity Webinar
 
Igniting Next Level Productivity with AI-Infused Data Integration Workflows
Igniting Next Level Productivity with AI-Infused Data Integration WorkflowsIgniting Next Level Productivity with AI-Infused Data Integration Workflows
Igniting Next Level Productivity with AI-Infused Data Integration Workflows
 
AI Fame Rush Review – Virtual Influencer Creation In Just Minutes
AI Fame Rush Review – Virtual Influencer Creation In Just MinutesAI Fame Rush Review – Virtual Influencer Creation In Just Minutes
AI Fame Rush Review – Virtual Influencer Creation In Just Minutes
 
Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1
 
Linked Data in Production: Moving Beyond Ontologies
Linked Data in Production: Moving Beyond OntologiesLinked Data in Production: Moving Beyond Ontologies
Linked Data in Production: Moving Beyond Ontologies
 
COMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a WebsiteCOMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a Website
 
Machine Learning Model Validation (Aijun Zhang 2024).pdf
Machine Learning Model Validation (Aijun Zhang 2024).pdfMachine Learning Model Validation (Aijun Zhang 2024).pdf
Machine Learning Model Validation (Aijun Zhang 2024).pdf
 
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
 
Designing A Time bound resource download URL
Designing A Time bound resource download URLDesigning A Time bound resource download URL
Designing A Time bound resource download URL
 

Agility v7.0-rro

  • 1. Rex Osborn HealthCare Informatics Idea Architect Agility Health International 1
  • 3. Introduction A practical bridge between BioInformatics & HealthCare IT… 4
  • 4. I. The Idea II. The Market III. Patentable Technology IV. Defining Personalized Medicine V. Relevance of Personalized Medicine VI. Challenges of Personalized Medicine VII.Pharmacogenomics VIII.Cost Impetus IX. Closed Loop Medication / Genome enabled X. Sequencing to DICOM 5
  • 5. The Idea Today bioinformatics & healthcare information technology (HIT) does not provide a practical nexus. The scientific & clinician genomic model is dissimilar & does NOT take into consideration; clinician workflow, HIT standards, CPOE & the rightful place within ―closed-loop-medication‖ to ensure patient safety. Without bridging bioinformatic & HIT - ―Personalized Medicine‖ will never be realized. Challenges in the exponential size of genomic data & controversy in how to manage that data is the gateway for credibility & revenue. Agility Genomics has a plan and engineering approach , as well as the team to bridge the Pharmacogenomic components of bioinformatics to the EHR. Making sequenced DNA clinically relevant. Furthermore we enable Personalized Medicine by providing clinically germane genome data to the patient’s PHR. Today intelligent storage, tomorrow the management of secondary data. 6 Practical interoperability; BioInformatics & the EHR
  • 6. The Idea We propose a new business that provides “sequenced” Genomic storage, management & clinical decision content for CPOE / EHR solutions; Bridging BioInformatics capacity to manage a sequenced genome into a practical HL7 feed for clinicians EHR Phase I. Genomic Data Storage (DICOM / HL7) – National Library of Medicine / National Institute Health Genomic Program / Grant (Genome raw data to DICOM) Phase II. Apply Intelligent HSM & HIPAA encryption to genetic data elements Phase III. Develop genomic ―ontology‖ leveraging standards to initiate parsing & aggregation of structured data (HealthLanguage) Phase IV. Develop clinical decision support (CDS) mechanism to convey Pharmacogenomic data @ the point of care (CPOE) (www.warfarindosing.org) Phase V. Commercialize DNA archive & analysis for forensic products (Services: storage, integration & aggregation to HL7) 7 Clinical Annotation of Patient Genomic Data within the EHR
  • 7. The Approach STORAGE OF WHOLE PATIENT GENOMES ACCESSIBLE VIA YOUR EHR  DICOM-based format w/ HL7 relevant data (MPI, PIX, PID etc)  Fast transfer in & out of EHR  Parsing, aggregation & mining for public / research / private output PHARMACOGENOMIC CLINICAL DECISION SUPPORT (CDS)  Generic algorithms for the EHR  Tethered, secure service  Drug – Genome clinical content for critical decision making @ POC ―CPOE‖ NOSOLOGY-BASED GENOME SEARCH FUNCTIONS: EHR  Provides clinician quick search to identify disease mutations  Will also offer OTS applications for genome analysis – M&A  Disease predisposition characteristic availability Agility sells software, services & secure cloud access through EHR & PHR suppliers. Leveraging our work with research institutions sharing, storing and managing genetic data packets. Our adherence to HIPAA, GINA, DICOM, HL7, HIPAA will enable a practical path to Personalized Medicine (healthcare tailored to each individual's genetic makeup). www.warfarindosing.org 8
  • 8. The Market Market Impetus: According to the report: Currently, it costs about $1,000 to sequence an entire human genome; That cost will be lowered to about $100 per patient by the year 2012, making it feasible to sequence individual patient genomes & store them in the EHR. Upside for Agility = the cost of storage and of the analyzed genome will be significant. The core diagnostic and therapeutic segment of the market – comprised primarily of pharmaceutical, medical device & diagnostics companies – is estimated at $24 billion and is expected to grow by 10 percent annually, reaching $42 billion by 2015. Market Size; The market for Personalized Medicine in the United States is already $232 billion, and it is projected to grow 11% annually, according to a new report published today by PricewaterhouseCoopers LLP The personalized medical care portion of the market – including telemedicine, health information technology & disease management services offered by traditional health & technology companies – is estimated at $4 billion to $12 billion and could grow tenfold to over $100 billion by 2015 if telemedicine takes off. The related nutrition and wellness market – including retail, complementary and alternative medicine offered by consumer products, food and beverage, leisure and retail companies – is estimated at $196 billion and is projected to grow 7 percent annually to over $290 billion by 2015. 9
  • 10. Patentable Technology 1) A DICOM Method for Storage of Human Genomic Data 2) Searchable Human Genomic Data by Nosology 3) Generalized, Allele-Specific Algorithms for Pharmacogenetic Clinical Decision Support (CDS) 4) Fast Transfer of Genomic Data to an XML-based Electronic Health Record (EHR) 5) Genomic-based XDS clinical connectivity (associate relevant clinical documentation) 6) Clinical content with ―ontology‖ for CPOE CDS solutions (conveyance method) 7) Genomic data encryption & access audit (HIPAA based) that meets GINA (2008 Genomic Legislation) 8) Patent transition methodology moving ―sequenced DNA‖ raw data to DICOM stored for conveyance to output of HL7 message relaying clinical content to CDS / CPOE / EHR 11
  • 11. Defining Personalized Medicine Personalized Medicine—also called Genome-based or Genomic Medicine Personalized Medicine analyzes a person’s molecular information to determine their propensity for developing certain diseases, including a disease’s potential onset & course. It also determines a person’s susceptibility for responding to different drug therapies, by determining the ability to metabolize drugs &/or likelihood of experiencing adverse drug reactions (ADR). The term personalized medicine is often used in place of the scientific term Pharmacogenomics. Bioinformatics is using computers to solve problems in biology. Bioinformatics is a scientific discipline that encompasses all aspects of biological information acquisition, processing, storage, distribution, analysis and interpretation. Bioinformatics combines the tools of Biology, Chemistry, Mathematics, Statistics & Computer Science to understand and model biological processes. Genetics is the study of heredity & genetic medicine, it examines the role of individual genes as they relate to biology and medicine. Genomic medicine makes use of our own personal (thus the name, personalized medicine) genome - our individual genetic structure encoded by the nucleotide sequences, etc. to determine an individuals vulnerability to disease and responsiveness to medication. Personalized Medicine is the Outcome of Genomic Medicine 12
  • 12. Relevance of Personalized Medicine Goals of Personalized Medicine allowing clinicians to…  Predict Disease pre-symptomatically with simple testing  Prevent Disease by identifying risks, early interventions  Diagnose Conditions less invasively, more accurately  Select Drugs that maximize benefits & minimize risks  Calibrate Treatments to heighten proven efficacy & recovery  Stable Genomics (Inherited Genes) – BRCA 1 & 2 predictor of breast and ovarian cancer risks – LDLR and APOB predictor of developing early coronary artery disease – MODY 1-6 predictor of MODY diabetes; subtypes affect treatment choice – CYP2D6/C19 Main cytochrome P450 genes that affects drug metabolism  dosing – CYP2C9/VKORC1 variants in these cP450 genes affect warfarin metabolism – TPMT guides adjustment of Purinethol dosing in Acute Leukemia patients Treat/Cure Disease using our own genes Dynamic Genomics (Gene Expression, Biomarkers…) – Estrogen Receptor predicts response to Tamoxifen in breast cancer – HER-2 Receptor predicts response to Herceptin in breast cancer – PSA predicts risk of prostate cancer – Cholesterol predicts risk of heart disease and strokes – HIV Genotyping to guide selection of therapy – PET Scans to diagnose and help manage treatment options for various cancers 13 Practical Use of Genomic Medicine
  • 13. Challenges of Personalized Medicine Application of data integration concepts & approaches to genomic medicine  Data warehouse approaches  Database federation approaches  Peer data management system approaches  Ontologies  Semi-structured data Gaps remaining in data integration both clinical & research to facilitate genomic medicine  Data availability  Privacy issues (HIPAA)  Data issues  Scalability  Standards adoption Bridging disciplines: collaborations vs convergence TACTICALLY  Storage - large and diverse data sets.  Intelligent Hierarchical Archive Management  DICOMization of Raw Data  Integration of HL7 data; MPI, CDR & History  National Library of Medicine (NLM) = Genetic Data Management ―Research‖  HIPAA – Genetic Data Encryption STRATEGICALLY  Ontology – MeSH, UMLS, Ontofusion, SnoMeds  Patent Workflow, Management, Parsing, Aggregation & Mining  XDS  Limited tools for appropriate standardization of findings  CRO – Clinical Research Organization  Genome based CDS  Provide genomic content for CDS 14
  • 15. Commoditization  The cost of sequencing and analysis of an entire human genome will drop to about $100 by 2012 (from Dr. George Church, Broad Institute, MIT/Harvard).  This will effectively require a new storage & data management scheme to handle Genomic data that has been sequenced.  Sequenced genomic data & analysis of this data to convey via a ―patentable‖ ontology in existing EHRs (the ability to communicate with disparate systems is a ―must‖)  Although Clinical Decision Support / Clinical Content is paramount & the ultimate goal for evidence based medicine, outcomes based medicine and to mitigate medication risk, the short term opportunity is in intelligent storage 16
  • 16. Historical trends in storage prices vs DNA sequencing costs 17
  • 17. Pharmacogenomics Opportunities will increase the value of the drugs being developed using Genomic / Genetic Medicine:  Obtain greater understanding of disease  Predict disease severity, onset, progression  Identify genetic subtypes of disease  Lower ADRs in Clinical setting  Lower unknown contraindications  Aid in discovery of new drug targets  Distinguish subgroups of patients who respond differently to drug treatment  Aid interpretation of clinical study results  Evolution of Pharmacogenetics – advancing requirements for research & clinical trial environments 18 Average Cost to Develop a Medication in the US $800 Million USD
  • 18. Evaluate Order Obtain medication related history Sequenced Genomic Data; Managed, Archived, Parsed, Aggregated & available @ the Point of Care CPOE Documentati on medication history & updates Intervene as indicated for ADR errors Select Medication Prepare Medication Dispense / Dist. IV & Medication CIS/CDS /CDR Assess & document patient response to medication according to defined parameters Closed Loop Medication Workflow w/ Genomic CDS Educate patient regarding medication Educate staff regarding medications 19
  • 19. Sequencing to DICOM MAPPING Identify set of clones that span region of genome to be sequenced LIBRARY CREATION Purify DNA from smaller clones Setup & perform sequencing chemistries Make sets of smaller clones from mapped clones TEMPLATE PREPERATION Determine sequences from smaller clones Specialty techniques to produce high quality sequences DATA EDITING / ANNOTATION GENOME SEQUENCING PRE-FINISHING & FINISHING Quality assurance Verification Biological annotation Submission to public DB 21
  • 20. Clinical Decision Support  Today, at best …  Population based-evidence combined with individual clinician experience  Calculators, nomograms and criteria to risk stratify individuals Clinical Decision Support - The act of providing clinicians, patients and other health care stakeholders with pertinent knowledge and/or person specific information, intelligently filtered or presented at appropriate times  CDS systems with 4 critical features significantly improved clinical practice in 94% of RCTs  Tomorrow, decision making will be …  Phenotype, environmental, clinical, and genomic factors in a ―black box‖ risk model  Patient and physician will need to interpret meaning of risk  Personalized medicine complements evidence-based medicine (Kawamoto et al., 2005): 1) automatic provision of CDS as part of clinician workflow 2) provision of recommendations 3) provision of CDS at time & location of decision making 4) computer-based generation of the CDS 23
  • 22. Workflow Agility Software - Input 1. Lab Test / Lab 2. DNA Sequence (SNPs & Genome) 3. DICOM Transport & Query Retrieve 4. Encryption & Audit Initiated 5. Genomic Research - Genotype 6. Screening – Genotype 7. Molecular / Medical Imaging – Genotype, Phenotype & Environment Agility Future Software & Services 10. Integrated – Genotype & Phenotype assessment for inherited & common conditions 11. EHR Portal enabled 12. Genome-based Clinical Decision Support (clinical content or ―full‖ logic for direct CPOE communiqués) 13. Provider Portal enabled 14. Public health / syndromic Portal enabled 15. PHR Portal enabled Agility Software & Services - Output 8. Archive 9. Research Database – parsing, aggregation & mining 10. Interface (current chasm) – LIS, PACS / RIS, CVIS, HIS, EHR & EDMS (Electronic Doc Mgt. System) 25
  • 23. Building Blocks PERSONALIZED Biologic Sciences Informatics & HCIT Molecular Basis of Disease Novel Therapies Disease Subtypes MEDICINE EHR Adoption BioStat Modeling Molecular Diagnostics Clinical Database ―Data warehouse‖ Genomics Epigenetics Proteomics 26
  • 24. Marketing Considerations Marketing Strategy  Competitive Positioning  Brand Strategy  Pricing  Distribution Channels  Sales Process  Marketing Campaigns  Marketing Plans Managing Sales & Marketing  Business Development  Telemarketing  Sales Management  Direct Mail  Email Marketing  Search Engine Marketing  Trade Shows  Publicity  Customer Retention  Traditional Media  Online Advertising  Social Media Tools & Processes  Naming  Messaging  Corporate Identity  Sales Literature (Collateral)  Sales Content  Website - Blog  CRM 27
  • 25. Horizontal Styled SWOT Strength Weakness Incredible growth, and investment Tactically we can leverage Existing Client Base • Highlight storage, scalability & encryption • Flexibility of HSM • Cloud Computing / Archiving • Huge Data Sets Integration chasm & output requires investment & development of software, resources & related services. Requires a move to a new clinical & bioinformatics vertical. Opportunity Evolution of Image archiving means going beyond the walls of Radiology & Cardiology – diversification of current product suite offers advantages as does growing market & new discipline. HHS will require genomic data embedded in to the EHR 2012 enforcement 2014 Threat Market vertical is growing & commoditization will require FDA to regulate & CMS to make procedure viable ―reimbursement challenge‖ ―genomic information exchange‖ very academic presently – the move from Bio to HIT has challenges 28
  • 26. Reference Material        The Human Genome Project: www.genome.gov The NUGene Project: www.NUGene.org Clinical Proteomics Project: http://proteomics.cancer.gov The FDA and Genomics: www.fda.gov/cder/genomics The CDC and Genomics: www.cdc.gov/genomics/default.htm NIH & Pharmacogenetics: www.nigms.nih.gov/Initiatives/PGRN Non-Profit Organizations  http://bioitalliance.org  http://www.personalizedmedicinecoalition.org  News and Updates  http://www.ageofpersonalizedmedicine.org  http://www.genomenewsnetwork.org/ 29
  • 29. Gene regulation: TIGR MeV + CAVEman Gene expression datasets are initially analysed using the MultiExperiment Viewer. Patterns of interest are visualized as animated color maps directly on the chosen organs. 32
  • 30. Pharmacokinetics 500mg Aspirin (acetylsalicylic acid) example Processes: Absorption > distribution > metabolism > excretion (ADME) Systems: alimentary > cardiovascular > urinary 33
  • 31. 4D ADME Visualization (a) (Absorption, Distribution, Metabolism, Elimination) ABSORPTION The original compound (e.g. acetylsalicylic acid or acetaminophen) is shown in red and is first absorbed through the digestive organs. 34
  • 32. 4D ADME Visualization (b) DISTRIBUTION, METABOLISM Simultaneously with its absorption into the blood stream, it is being metabolized into derivative compounds, shown in green (e.g. salicylic acid, acetaminophen sulfate, acetaminophen glucuronide, etc.), which are distributed throughout the body. 35
  • 33. 4D ADME Visualization (c) ELIMINATION Eventually all compounds are eliminated from the blood and are excreted through the urinary system 36
  • 34. Drug modeling: Aspirin, Tylenol, Prozac, Lipitor 37
  • 35. Exploring complex 4D data along any axis (with Dr. Benedikt Hallgrímsson, U of C) Sagittal Frontal Right: Integration, quantification and visualization of data in 3D / 4D Averaged Above: 3D morphometric (micro-CT) and cell proliferation (histochemistry) data in mouse embryos Embryo 2 Embryo 1 External 38
  • 36. Data integration mechanism Gene Expression Omnibus Terminologia Anatomica Cytomer GSM88529 : Cardiac A12.1.00.001 Heart Heart GSM88484 : Coronary artery A12.2.03.101 Right coronary artery Right coronary artery A12.2.03.201 Left coronary artery Left coronary artery A06.5.01.002 Right lung Left inferior pulmonary lobe A06.5.01.003 Left lung Middle lobe of right lung GSM88522 : Lung Left superior pulmonary lobe Right inferior pulmonary lobe Right superior pulmonary lobe Terminological discrepancies between ontologies make integration difficult. 39
  • 37. Ontology support: All data sources are connected Domains ontologies are semantically related. Data sources are indexed via ontologies. Visualization device may be either a virtual reality (e.g., CAVE) or a common desktop. 40
  • 38. Future research directions Model more molecular & anatomical processes Develop more variety of interactions Utilize more human body models – Female, child Genetic Variation Pathways Cellular Processes Phenotypes 41

Notas do Editor

  1. HHS 2012 regulatory for EHR / nexus of Bio & HIT
  2. Genomic Informatics - http://www.warfarindosing.org/Source/Home.aspx
  3. Genome Base Pairs
  4. Dr. Higgins - It’s not just genomic scientists that are dealing with enormous amounts of DNA sequence data – the clinician will soon be next. However, the explosion in linking disease with genetics, and the realization that the FDA will require gene testing prior to the prescription of potentially hundreds of drugs, will challenge the storage capacity required for clinical data. In addition, recent studies have shown the utility of whole genome analysis (6 billion bases of DNA per individual), discovering a cause of Charcot-Marie-Tooth disease, one of the most commonly inherited neurological disorders, which affects approximately 1 in 2500 people. In addition, other disease-causing genes have also recently been found by looking in families that inherit a variety of different types of mutations.This is no longer the “spit-test” parties and subsequent Single Nucleotide Polymorphism (“SNiP”) analysis that Direct-to-Consumer companies offer to consumers, often only showing modest increased risk for disease prediction (typically ranging from 1.3 – 1.8 fold greater than another individual).Ironically, the mutations that lead to Adverse Drug Events often convey a 100 – 10000+ fold greater risk for that patient.“There will be an explosion of family sequencing that will identify disease genes,” Dr. Leroy Hood, Director of the Institute for Systems Biology, said in a recent interview. “My prediction is that most of us will have our genome sequences done, included as part of our medical records, and it will be an important part of predictive medicine.” This suggests that “all Healthcare IT systems will soon be overwhelmed by patient genomic and pharmacogenomic data.”As stated by Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics, said in a Newsweek interview, - The message is not "Here's your destiny. Get used to it!" Instead, it's "Here's your destiny, and you can do something about it!" Diseases result from a combination of genetic vulnerability and lifestyle. If you know you have high risk of certain diseases, it's in your interest to know and practice the lifestyle that reduces your risk—and the younger, the better.”The latest research findings have started a “tsunami” in looking at the entire genome in patients with both Mendelien traits and those with common, complex diseases. This has created a need for more computing resources. For example, Washington University’s current scientific and clinical genomic data center, a 16,000-square-foot facility that houses approximately 5,000 processors and more than 5 petabytes of disk storage, is nearly 90 percent full. The University just received a $14M grant from the National Institutes of Health to increase storage capacity.At least 30% of disease has a primary genetic cause, yet we are still in the discovery phase of genomic medicine. Given the exponential rate of change in disease-gene causation & individual variation related to healthcare, we estimate that within 5 years, genetic testing will be the most common laboratory test in several specialties, including oncology, cardiovascular disease, Type II diabetes, psychiatry & neurology.
  5. http://Single Nucleotide Polymorphism (“SNiP”) analysis that Direct-to-Consumer companies offer to consumers, often only showing modest increased risk for disease predictiowarfarindosing.org/Source/Home.aspxDr. Higgins - It’s not just genomic scientists that are dealing with enormous amounts of DNA sequence data – the clinician will soon be next. However, the explosion in linking disease with genetics, and the realization that the FDA will require gene testing prior to the prescription of potentially hundreds of drugs, will challenge the storage capacity required for clinical data. In addition, recent studies have shown the utility of whole genome analysis (6 billion bases of DNA per individual), discovering a cause of Charcot-Marie-Tooth disease, one of the most commonly inherited neurological disorders, which affects approximately 1 in 2500 people. In addition, other disease-causing genes have also recently been found by looking in families that inherit a variety of different types of mutations.This is no longer the “spit-test” parties and subsequent n (typically ranging from 1.3 – 1.8 fold greater than another individual).Ironically, the mutations that lead to Adverse Drug Events often convey a 100 – 10000+ fold greater risk for that patient.“There will be an explosion of family sequencing that will identify disease genes,” Dr. Leroy Hood, Director of the Institute for Systems Biology, said in a recent interview. “My prediction is that most of us will have our genome sequences done, included as part of our medical records, and it will be an important part of predictive medicine.” This suggests that “all Healthcare IT systems will soon be overwhelmed by patient genomic and pharmacogenomic data.”As stated by Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics, said in a Newsweek interview, - The message is not "Here's your destiny. Get used to it!" Instead, it's "Here's your destiny, and you can do something about it!" Diseases result from a combination of genetic vulnerability and lifestyle. If you know you have high risk of certain diseases, it's in your interest to know and practice the lifestyle that reduces your risk—and the younger, the better.”The latest research findings have started a “tsunami” in looking at the entire genome in patients with both Mendelien traits and those with common, complex diseases. This has created a need for more computing resources. For example, Washington University’s current scientific and clinical genomic data center, a 16,000-square-foot facility that houses approximately 5,000 processors and more than 5 petabytes of disk storage, is nearly 90 percent full. The University just received a $14M grant from the National Institutes of Health to increase storage capacity.At least 30% of disease has a primary genetic cause, yet we are still in the discovery phase of genomic medicine. Given the exponential rate of change in disease-gene causation & individual variation related to healthcare, we estimate that within 5 years, genetic testing will be the most common laboratory test in several specialties, including oncology, cardiovascular disease, Type II diabetes, psychiatry & neurology.
  6. Dr. Higgins - It’s not just genomic scientists that are dealing with enormous amounts of DNA sequence data – the clinician will soon be next. However, the explosion in linking disease with genetics, and the realization that the FDA will require gene testing prior to the prescription of potentially hundreds of drugs, will challenge the storage capacity required for clinical data. In addition, recent studies have shown the utility of whole genome analysis (6 billion bases of DNA per individual), discovering a cause of Charcot-Marie-Tooth disease, one of the most commonly inherited neurological disorders, which affects approximately 1 in 2500 people. In addition, other disease-causing genes have also recently been found by looking in families that inherit a variety of different types of mutations.This is no longer the “spit-test” parties and subsequent Single Nucleotide Polymorphism (“SNiP”) analysis that Direct-to-Consumer companies offer to consumers, often only showing modest increased risk for disease prediction (typically ranging from 1.3 – 1.8 fold greater than another individual).Ironically, the mutations that lead to Adverse Drug Events often convey a 100 – 10000+ fold greater risk for that patient.“There will be an explosion of family sequencing that will identify disease genes,” Dr. Leroy Hood, Director of the Institute for Systems Biology, said in a recent interview. “My prediction is that most of us will have our genome sequences done, included as part of our medical records, and it will be an important part of predictive medicine.” This suggests that “all Healthcare IT systems will soon be overwhelmed by patient genomic and pharmacogenomic data.”As stated by Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics, said in a Newsweek interview, - The message is not "Here's your destiny. Get used to it!" Instead, it's "Here's your destiny, and you can do something about it!" Diseases result from a combination of genetic vulnerability and lifestyle. If you know you have high risk of certain diseases, it's in your interest to know and practice the lifestyle that reduces your risk—and the younger, the better.”The latest research findings have started a “tsunami” in looking at the entire genome in patients with both Mendelien traits and those with common, complex diseases. This has created a need for more computing resources. For example, Washington University’s current scientific and clinical genomic data center, a 16,000-square-foot facility that houses approximately 5,000 processors and more than 5 petabytes of disk storage, is nearly 90 percent full. The University just received a $14M grant from the National Institutes of Health to increase storage capacity.At least 30% of disease has a primary genetic cause, yet we are still in the discovery phase of genomic medicine. Given the exponential rate of change in disease-gene causation & individual variation related to healthcare, we estimate that within 5 years, genetic testing will be the most common laboratory test in several specialties, including oncology, cardiovascular disease, Type II diabetes, psychiatry & neurology.
  7. Currently, it costs about $5,000 to sequence an entire human genome; That cost will be lowered to about $100 per patient by the year 2012, making it feasible to sequence individual patient genomes & store them in the EHR. Upside for Agility = the cost of storage and of the analyzed genome will be significant.Market Size; The market for Personalized Medicine in the United States is already $232 billion, and it is projected to grow 11% annually, according to a new report published today by PricewaterhouseCoopers LLP. The core diagnostic and therapeutic segment of the market – comprised primarily of pharmaceutical, medical device & diagnostics companies – is estimated at $24 billion and is expected to grow by 10 percent annually, reaching $42 billion by 2015.NOTE: personalized medical care portion of the market – including telemedicine, health information technology & disease management services offered by traditional health & technology companies – is estimated at $4 billion to $12 billion and could grow tenfold to over $100 billion by 2015 if telemedicine takes off.The related nutrition and wellness market – including retail, complementary and alternative medicine offered by consumer products, food and beverage, leisure and retail companies – is estimated at $196 billion and is projected to grow 7 percent annually to over $290 billion by 2015.
  8. **In the United States, a Pharmacy Benefit Manager (PBM) is a third party administrator of prescription drug programs. They are primarily responsible for processing and paying prescription drug claims. They also are responsible for developing and maintaining the fomrulary, contracting with pharmacies, and negotiating discounts and rebates with drug manufacturers. Today, more than 210 million Americans nationwide receive drug benefits administered by PBMs. Fortune 500 employers, and public purchasers (Medicare Part D, the Federal Employees Health Benefits Program) — provide prescription drug benefits to the vast majority of American workers and retirees. The market is dominated by 3 large players – MEDCO, CAREMARK, and EXRESS SCRIPTS.Core BPM Services: Pharmacy networks — PBMs build networks of retail pharmacies to provide consumers convenient access to prescriptions at discounted rates. PBMs monitor prescription safety across all of the network pharmacies, alerting pharmacists to potential drug interactions even if a consumer uses multiple pharmacies.Mail service pharmacies — PBMs provide highly efficient mail-service pharmacies that supply home-delivered prescriptions with great accuracy and safety and at a substantial savings. In a 2005 report, the FTC determined that PBM-owned mail-order pharmacies offer lower prices on prescription drugs than retail pharmacies and non-PBM owned mail pharmacies; are very effective at capitalizing on opportunities to dispense generic medications; and have incentives closely aligned with their customers: the third-party payers who fund prescription drug care. The Government Accountability Office (GAO) has also found that mail-order pharmacies in the Federal Employees Health Benefits Program (FEHBP) offer substantial savings, especially when compared to retail pharmacies. According to January 2003 GAO report examining cost savings with mail-order pharmacies under FEHBP, the average mail-order pharmacy price for prescription drugs was 27 percent lower for brand name drugs and 53 percent lower for generic drugs than the price paid to retail pharmacies by cash-paying customers.According to GAO, “enrollees in the plans reviewed had wide access to retail pharmacies, coverage of most drugs, and benefited from cost savings generated by the PBMs. Enrollees typically paid lower out-of-pocket costs for prescriptions filled through mail-order pharmacies and benefited from other savings that reduced plans’ costs and therefore helped to lessen rising premiums.Formularies — PBMs use panels of independent physicians, pharmacists, and other clinical experts to develop lists of drugs approved for reimbursement in order to encourage clinically appropriate and cost-effective prescribing; PBM clients always have the final say over what drugs are included on the formulary that they offer to their employees or members.Plan design — PBMs advise their clients on ways to structure drug benefits to encourage the use of lower cost drug alternatives — such as generics — when appropriate.This is done by setting plans up with different copay tiers, in this case the client will apply a lower copay for generic drugs than it would for brand drugs. This forces the particiapents to use generic drugs, because the cost is much less than a brand drug. Plan designs can also be set up with Maximum Allowed Benefit (MAB) for clients that need to limit drug spend for financial reasons. The PBMs’ role is advisory only; the client retains all responsibility for establishing the plan design.Electronic prescribing (E-prescribing) — PBMs have pioneered the use of cutting-edge e-prescribing technology, which provides physicians with clinical and cost information on prescription options that allows them to better counsel consumers on which medications—including various lower cost options—will be the safest and most affordable choices. PBMs led the effort to increase the use of e-prescribing in Medicare.Financial incentives for physicians to adopt health information technology (HIT) included in the recent economic stimulus bill will increase the number of prescribers using e-prescribing to more than 75 percent over the next five years—nearly double the rate of use anticipated after passage of last year’s e-prescribing legislation.Research has found that e-prescribing will help prevent 3.5 million harmful medication errors and save the federal government $22 billion in drug and medical costs over the next 10 years, offsetting the projected $19 billion in federal outlays to modernize the nation’s HIT infrastructure under the American Recovery and Reinvestment Act (ARRA).Manufacturer discounts — PBMs pool purchasing power to negotiate substantial discounts from pharmaceutical manufacturers in order to lower benefit costs for clients and consumers.Clinical management — PBMs use a variety of tools such as drug utilization review and disease management to encourage the best clinical outcomes for patients.***CRO – Clinical Research Organization - A clinical trial is a research project, involving patients or healthy individuals, to test new treatment modalities or medicine. Clinical trials help doctors find out if these treatments are safe, if they have any side effects, and if they are better than treatment options already available. Types f trials: Treatment trials test experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy. Prevention trials look for better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vitamins, vaccines, minerals, or lifestyle changes. Diagnostic trials are conducted to find better tests or procedures for diagnosing a particular disease or condition Screening trials test the best way to detect certain diseases or health conditions. Quality of Life trials (or Supportive Care trials) explore ways to improve comfort and the quality of life for individuals with a chronic illness.
  9. GINA = On May 21st, President Bush signed into law the Genetic Information Nondiscrimination Act (GINA), which prohibits U.S. insurance companies and employers from discriminating on the basis of information derived from genetic tests. GINA passed both houses of Congress with a vote in the U.S. House of Representatives of 414 to 1. The bill had passed in the House twice before, most recently last year when the vote was 420 to 3. The U.S. Senate unanimously passed the current bill after compromises were reached on areas of disagreement that had held up its passage for several months.GINA protects Americans from discrimination based on information derived from genetic tests. It forbids insurance companies from discriminating through reduced coverage or pricing and prohibits employers from making adverse employment decisions based on a person’s genetic code. In addition, insurers and employers are not allowed under the law to request or demand a genetic test. A 2001 study by the American Management Association showed that nearly two-thirds of major U.S. companies require medical examinations of new hires. In addition, 14% conduct tests for susceptibility to workplace hazards, 3% for breast and colon cancer, and 1% for sickle cell anemia; 10% collect information about family medical history. “Because of this legislation, Americans will be free to undergo genetic testing for diseases such as cancer, heart disease, diabetes, and Alzheimer’s without fearing for their job or health insurance,” said House speaker Nancy Pelosi (D-Calif.) in a statement. Increased genetic testing makes it more likely that researchers will come up with early, lifesaving therapy for a wide range of diseases with hereditary links, lawmakers said. Genetic testing also will help doctors catch problems early, perhaps leading to preventive treatment and lower costs.
  10. The foundation of Personalized Medicine – Genomic & Genetic Medicine; Understanding Molecular Medicine, through both laboratory and imaging techniques, deepens our ability to detect, diagnose and treat disease. Genomics / Genetics, the study of genes / heredity, is the most common area of study since it involves a stable, albeit large, data set. Genomic data is particularly useful in identifying certain diseases, unveiling risk factors for other diseases, and predicting how well certain drugs will work in humans. This last area, called pharmacogenomics, is an increasingly popular area of study involving both drug effectiveness (efficacy) and drug side effects (contraindications). This is a critical field since many medications are only effective in 50% of the population and cause side effects in another large percentage, but we don’t know ahead of time how individuals will react. Being able to test for gene differences ahead of time will both improve effectiveness and decrease side effects for patients. Other important areas of study include proteomics and metabolomics. While genetic markers are stable, these biomarkers are constantly changing as a function of both genetic and environmental exposures. They are particularly important in diagnosing diseases and calibrating treatment regimens. Dr. Higgins: “There are established Human Geneticists (M.D.s) who have been studying rare Mendelien disorders for over one hundred years. These are disorders like Huntington’s disease or Cystic Fibrosis in which 25-50% of the offspring typically inherit the disease, and up until recent DNA sequencing, no one knew thecause of these diseases. We still do not have a cure for most of these diseases. It is now recognized that, following the sequencing of the human genome, many small single mutations (called Single Nucleotide Polymorphisms or “SNiPs”) in the genome that form patterns that are diagnostic for more common, complex diseases like Type II Diabetes and Coronary Artery Disease. It appears that most human disease has a distinct genomic component. Finally, it is now known that the difference in the side effects and action of most drugs are aconsequence of individual genetic variation between patients – this leads to “Personalized Medicine”, where some drugs now require a “gene test” before they can be prescribed. Pharmacogenomics information is contained in about ten percent of labels for drugs approved by the FDA. Note: There are also breakthroughs in transciptomics, proteomics and metabolomics which are diagnostic markers of disease, and could be stored in the EHR. For example, a few (3) markers from cerebrospinal fluid, or many (18) proteins sampled from blood can predict Alzheimer’s disease.“Personalized Medicine” refers to the tailoring of medical treatment to the individual characteristics of each patient…to classify individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment.  Preventative or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not.”Diagnosing and Predicting Disease and Disease SusceptibilityAll diseases have a genetic component, whether inherited or resulting from the body's response to environmental stresses like viruses or toxins. The successes of the HGP have even enabled researchers to pinpoint errors in genes--the smallest units of heredity--that cause or contribute to disease.  The ultimate goal is to use this information to develop new ways to treat, cure, or even prevent the thousands of diseases that afflict humankind. But the road from gene identification to effective treatments is long and fraught with challenges. In the meantime, biotechnology companies are racing ahead with commercialization by designing diagnostic tests to detect errant genes in people suspected of having particular diseases or of being at risk for developing them.  An increasing number of gene tests are becoming available commercially, although the scientific community continues to debate the best way to deliver them to the public and medical communities that are often unaware of their scientific and social implications. While some of these tests have greatly improved and even saved lives, scientists remain unsure of how to interpret many of them. Also, patients taking the tests face significant risks of jeopardizing their employment or insurance status*. And because genetic information is shared, these risks can extend beyond them to their family members as well.  *Passing of the 2008 Genetic Information Non-descrimination Act should protect against such discrimination. May 2008. Disease InterventionExplorations into the function of each human gene--a major challenge extending far into the 21st century --will shed light on how faulty genes play a role in disease causation. With this knowledge, commercial efforts are shifting away from diagnostics and toward developing a new generation of therapeutics based on genes. Drug design is being revolutionized as researchers create new classes of medicines based on a reasoned approach to the use of information on gene sequence and protein structure function rather than the traditional trial-and-error method. Drugs targeted to specific sites in the body promise to have fewer side effects than many of today's medicines.  The potential for using genes themselves to treat disease--gene therapy--is the most exciting application of DNA science. It has captured the imaginations of the public and the biomedical community for good reason. This rapidly developing field holds great potential for treating or even curing genetic and acquired diseases, using normal genes to replace or supplement a defective gene or to bolster immunity to disease (e.g., by adding a gene that suppresses tumor growth).
  11. Today applied medicine involves disease prevention (e.g. guidance on diet & exercise habits), early detection of problems (e.g. Colonoscopy, Mammograms, Physicals), and treating a problem that has occurred. However, we are limited in each of these areas. For preventive care, our guidance could be more specific & could carry more weight if we had genetic testing to help a patient understand their risk. For early detection, we must rely on “macro” level events, such as visualizing polyps, feeling masses, imaging structural distortions, and tracking non-specific biomarkers (e.g. PSA). The field of molecular detection will help us to more quickly identify diseases and thus have more success in treating them before they spread or cause excessive damage. For disease treatment, we know that not all medications or other treatment options work for all patients. Molecular medicine has the ability to help us choose the best treatment regimens, as well as more easily follow the progression of disease over time. By The Numbers: The ambitions of healthcare providers have not changed in the past hundred years, but the capabilities certainly have. We are now unlocking the secrets of health at a molecular level – which includes not only why some people get diseases, but also how to prevent or cure them. Knowing this information is only valuable in the context of making it available for the right patient at the right time. There are 3 billion letters in the human DNA code. While more than 99.9 % of DNA is identical between any two humans, about one in every 1200 amino acid pairs varies from one person to another. These single nucleotide polymophisms (SNPs or SNiPs) are what differentiates us from each other. Furthermore, haplotypes are a set of SNPs on a single chromatid that are statistically associated. It is thought that these associations, and the identification of a few alleles of a haplotype block, can unambiguously identify all other polymorphic sites in its region. The causes of common disease are very complex. We know that both environment and genetics play important roles. Furthermore, most diseases, as well as responses to medicines, involve the interaction of multiple genes. Practical Use TodayBRCA1 gene mutations are associated with increased breast, ovarian, and possibly prostate, and colon cancers; while BRCA2 gene mutations are associated with breast, pancreatic, gallbladder, and stomach cancers. BRCA positive patients should get more aggressive monitoring, and some opt for even more aggressive measures including bilateral mastectomies and oopherectomies to minimize their future risk of breast and ovarian cancer. Several genes affecting the Cytochrome P450 pathway determine a patient’s ability to metabolize a large variety of medications. Depending on results, a patient is usually put into four categories of metabolism: Normal, Ultrarapid, Intermediate, and Poor. The ultrarapid group may therefore not respond well to normal dosages, while the Intermediate and Poor groups may suffer side effects related to the drug levels getting too high.About 20-30% of women with breast cancer are HER-2 positive (meaning they have too many copies of the HER-2 gene, and thus too much HER2 protein). These breast cancers are often more aggressive and harder to treat. Herceptin is a monoclonal antibody that specifically targets the HER-2 genes and thus is only effective for HER-2 positive cancers. The FDA therefore requires that molecular testing confirm elevated HER-2 levels before allowing physicians to prescribe Herceptin.
  12. Dr. Higgins There are several approaches to storing genomic data.If you store the entire genome of a patient - that's about 6 GB. Without annotation, if you multiply that by the 5M EHRs in the Microsoft EHR, that's 30 PB.Since 99.9% of human genomic data is identical, you can use a ‘sparse matrix’ approach, in which you only store the differences in genomes between individual patients. However, this requires another layer of analysis to understand where the genomic sequences differ.Finally, and most importantly at this moment in time, we have been using microarray data (from DNA, RNA or protein). In the case of the human genome there are about 6M Single Nucleotide Polymorphisms (SNP), that is, single base changes (A, C, G or T), that differ between individuals. These can be predictive for common diseases, as stated above.Some challenges:On the data storage side: For a few patients or samples, it may be possible to store primary data, but the cost of professional storage, backup, maintenance, electricity and transfer is huge. Here, we are not talking about the high street hard disks, but the professional raid arrays which store data reliably.The Sanger Hinxton Institute has one of the largest data centers in the world, and they have just now completed the majority of 1000 genomes project and few other genomics projects. The storage requirement is sky-rocketing. Imagine the real time data, where the patients are unlimited - ie several On the data transfer side: Moving huge data across places would also lead data congestion. For the large hadron collider data, they have built their dedicated network. But, most rely on the internet. We can have one facility (per city or state or region wise) which is common for several hospitals. If the patient is moving within region for a different hospital, the same facility would be able to serve without moving data. This also aids in cost-cutting and maintenance issues. On the sample side: It clearly depends on a case by case basis. If you have an important, hard-to-get sample, deleting the primary data is not good. But, in many cases where the patient sample (nowadays, we can have cheap/efficient saliva kits - no need for blood samples) can be re-obtained or stored, AND you vaguely know that the data analysis is required only once, at least the primary data can be deleted.Again, moving them across hospitals is not a viable option in the long time. Having a facility integrated with data center (regional basis) is the option. Classifying samples based on various factors, and applying rules is a good option.On the data format side: This should evolve a lot in (gen)-omics. There are several new data format types/potentials on the informatics side, which would reduce the size of data (without loss) on a per genome basis. This will again not help us in keeping _all_ data, but would let us store more (millions) patients'.
  13. It is estimated that less than 10% of disease-causing mutations have been discovered in the human genome. These range from monogenic diseases like Huntington’s disease and Cystic Fibrosis, to mutations that cause variability in drug response between individuals, to variation in Copy Number that lead to diseases like childhood Autism, to Single Nucleotide Polymorphisms (SNPs) that may form patterns that contribute to common, complex diseases like Type II Diabetes and Coronary Artery Disease.
  14. Dr. Leavitt (Original ONC Chief 2007) “Personalized health care will combine the basic scientific breakthroughs of the human genome with computer-age ability to exchange and manage data…. Increasingly it will give us the ability to deliver the right treatment to the right patient at the right time – every time.”
  15. Dr. Leavitt (Original ONC Chief 2007) “Personalized health care will combine the basic scientific breakthroughs of the human genome with computer-age ability to exchange and manage data…. Increasingly it will give us the ability to deliver the right treatment to the right patient at the right time – every time.”We stand at the dawn of a new understanding of disease…Nature 409, 860 - 921 (2001)Initial sequencing and analysis of the human genome International Human Genome Sequencing ConsortiumThe human genome holds an extraordinary trove of information about human development, physiology, medicine andevolution. Here we report the results of an international collaboration to produce and make freely available a draft sequence of thehuman genome. We also present an initial analysis of the data, describing some of the insights that can be gleaned from the sequence.
  16. Services / Software Nexus Bioinformatics & PharmacogenomicsKnowledge DiscoveryIdentification of potential drug targetsGenomicsProteomicsCheminformaticsDrug target modelingDrug optimizationSimulating drug effects on pathwaysEstimating toxicological effects
  17. We will use "personalized medicine" as a conveyer of genomic informatic data (and management) to an existing EHR.  Agility does this leveraging interoperability standards, a unified medical language and a layer of intelligent clinical content (for existing clinical decision support systems, CPOE solutions and as an easy add on for medication Management "eMAR" and or Order Management Applications.Critical Data Needed:Need for data standardizationGenomic data + traditional clinical dataNeed to effectively deliver complex information in busy practice settings E.g., primary careNeed for widely deployable CDS systemsIn settings with different EHR systems (or none at all)
  18. http://www.ornl.gov/sci/techresources/Human_Genome/faq/seqfacts.shtmlQuality Analysis: This step is crucial as it means we can have  confidence in the results obtained in subsequent analyses, excluding the risk that  final conclusions result from poor quality  biases in the data. Biostatisticsis the application of computational and statistical techniques to biology, in order to give statistical credibility to  data: It shows to what extent  an observation  is the result of  experimental design and  not a consequence of  chance. Data Mining aims to further analyze the biostatistical results (for example, differentially expressed genes, single nucleotide polymorphisms, portions of chromosomes  showing  copy number variations), in order to extract the most relevant biological information (inference of pathways, gene ontology, functional annotation,...). Genome Analysis and Annotation: Through strong partnerships, we provide tailored  automated genome annotation tools for prokaryotic and eukaryotic genomes.
  19. Sequencing - http://www.illumina.com/Over the past decade, DNA sequencing throughput has increased over 50-fold. Advances in DNA sequencing have enabled logarithmic growth of data points and breadth in coverage of an individual genome. High-throughput sequencing holds great promise for population-wide analysis that may influence treatment of human diseases, development of prognostic genetic biomarkers, elucidation of somatic cancer-generating mutations, or viral drug-resistance. However, considerable collection, processing, and analysis costs remain and still impede studies involving multiple samples. If the cost of a single genome analysis were lowered, without jeopardizing performance standards, many previously impractical studies could become an everyday reality. The key challenges in achieving this goal are miniaturization of the reactions and increase in quantity and density of reactions. The same volume previously occupied by a single reaction now contains millions of reactions, proportionally decreasing per-reaction cost. New technologies aim to achieve price-performance points that bring the cost to process a human genome on par with the cost of the bacterial genome, ultimately aiming for a coveted goal of $1,000 per genome. Most of the current applications are based on the comparison of already sequenced genomes. Re-sequencing of an entire genome can be successfully accomplished with short reads of about 30 bp, as long as the coverage is somewhere between 25–30x. This paradigm shift gave a boost to short-read technologies.
  20. Reduce the cost of storage & emphasize DICOM expertise, ability to work within HIPAA guidelines. Integration expertise, & initial focus on research to garner tactical grants.
  21. Genomic Informatics - http://www.warfarindosing.org/Source/Home.aspx